Clearpoint Neuro (CLPT) investor relations material

Executive summary

• Q3 revenue rose 36% YoY to $12.075M; growth came from IRRAflow sales, CAL services and higher capital-equipment placements.

• Net loss widened to $7.460M from $5.891M; gross margin declined to 58% from 63%.

• 2026 revenue guidance is $48.0M–$50.0M; management described mid-teens 2027 base-business growth as an early view, not official guidance.

Financial highlights

• Q3 product revenue was $7.9M (+47% YoY); service and other revenue was $4.2M (+20%); gross profit was $7.1M versus $5.6M.

• Q3 operating expenses rose 23% to $13.4M from $10.9M; operating loss was $6.332M versus $5.276M, and diluted loss per share was $0.24 versus $0.21.

• 9M revenue was $35.083M versus $26.561M; product revenue totaled $24.1M (+45%) and service and other revenue $11.0M (+11%).

• 9M net loss widened to $28.349M from $17.754M; operating loss was $25.054M versus $17.119M, and diluted loss per share was $0.94 versus $0.63.

Outlook and guidance

• 2026 revenue is estimated at $48.0M–$50.0M; Q4 growth could come from capital equipment, disposables and CAL services, though equipment installations can shift between periods.

• Mid-teens base-business revenue growth is a reasonable 2027 view, not official guidance; further insight is expected in January following clinical, regulatory and CAL developments.

• Current forecasts indicate cash can fund operations and obligations for at least 12 months from financial-statement issuance; continued net losses are expected during commercialization and development.

• Operational burn is expected to decline gradually QoQ over the next four to six quarters as revenue growth outpaces OpEx; CAL capital expenditures are expected over the next 12 months.